Viatris (VTRS), a leading biotech company, has had its share of ups and downs based on various business and economic incidents. The company's stock has seen fluctuations, with several days of gains and losses. Their CEO's 2024 pay has been revealed and Truist has initiated their coverage with a 'Buy' rating and a $15 PT. Viatris has shown signs of recovery and the company was named in Forbes' list of the world's best employers for the fifth consecutive year. It seems like they are expected to beat estimates in their future earnings report. The company made strides legally with the approval of its amended bylaws. They also gained FDA approval for the first generic Iron Sucrose Injection, marking their entry into a $515M IV Iron market. Viatris also finally completed its acquisition of Aculys Pharma, highlighting their solid expansion strategy. Their Q2 results were above estimates, boosting their stock. Nonetheless, they face potential class action over FDA inspection fallout and their stock underperformed compared to Nasdaq. They remained strong and scheduled their Q3 2025 financial results and investor conference call.
Viatris VTRS News Analytics from Thu, 27 Feb 2025 08:00:00 GMT to Fri, 24 Oct 2025 21:25:00 GMT -
Rating 2
- Innovation -4
- Information 7
- Rumor -1
